Faster sequencers, larger datasets, new challenges

Abstract

The Advances in Genome Biology and Technology (AGBT) meeting this year maintained its reputation for being one of the few international scienti c conferences that places revolutionary technology and groundbreaking science on an equal footing. Throughout the meeting, attendees had the opportunity to learn about the latest scienti c research fueled by genome technologies while being exposed to many technological breakthroughs that may soon power the next generation of sequencers.

Next Generation Sequencing - Advances, Applications and Challenges

“…Third generation sequencing (3GS) theoretically promises many advantages over existing 2GS methods including higher throughput, longer read lengths, improved accuracy and requiring smaller amounts of starting material [74], indeed some companies e.g. Oxford Nanopore Technologies, are promising single molecule sequencing [75,76]. The potential of single molecule nanopore sequencing is particularly exciting for researchers working in the field of DNA methylation.…”

Bacteriophage Orphan DNA Methyltransferases: Insights from Their Bacterial Origin, Function, and Occurrence

“…A particular type of new generation sequencing technology has provided an alternative, fast, and attractive approach. Pacific Biosciences SR DNA sequencing technology is a recent high-throughput sequencing platform that can generate average read lengths of over 2,500 bp of whole phage genomes (96). Despite initial high error rates, on-going improvements of the technology and software have greatly increased read accuracy (97,98).…”

Rapid and cost-effective molecular diagnosis using exome sequencing of one proband with autosomal dominant congenital cataract

“…32 This sequencing process can probably be shortened to about 17 h when using the new model Illumina HiSeq 2500 to do the whole-exome sequencing. 33 By focusing on 18 ADCC genes, the completion of bioinformatics analysis could be controlled within only 5 h. The total turnaround time is feasible for clinical molecular diagnosis.…”